

1

Introduction

2

Executive
summary

3

Research
areas
and groups

4

Associated
clinicians



3.3.3 Immuno-Rheumatology Group

Publications: 55 | Q1: 38

COMPOSITION

María Eugenia Miranda Carús.
Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

- **Pilar Aguado Acín.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Balsa Criado.** *Jefe de Sección de Reumatología. Hospital Universitario La Paz/ Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Gema Bonilla Hernán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Ana Castilla Plaza.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Eugenio de Miguel Mendieta.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Francisco de Borja Hernández de Breijo.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Paula Fortea Gordo.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Sara García Carazo.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Emilio Martín Mola.** *Jefe de Servicio de Reumatología. Hospital Universitario La Paz/ Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Ana Martínez Feito.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Irene Monjo Henry.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*



- **María Victoria Navarro Compán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Laura Nuño Nuño.** *Médico Adjunto Interino en Reumatología. Hospital Universitario La Paz*
- **María Dora Pascual-Salcedo Pascual.** *Químico Adjunto en Inmunología. Hospital Universitario La Paz*
- **Chamaida Plasencia Rodríguez.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Diana Peiteado López.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Villalba Yllán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our objective is to investigate the pathogenesis and evolution of rheumatic diseases, specifically focusing on imaging, genetics, metabolic pathways and immunopathogenesis.

RESEARCH LINES

- Immunopathogenesis, genetic, evolution, prognosis and biomarkers of inflammatory and autoimmune arthritis
- Imaging of inflammatory and autoimmune arthritis
- Immunopathogenesis and genetics of osteoporosis
- Immunogenicity of biological therapies with monoclonal antibodies
- Immunopathogenesis, evolution, prognosis and biomarkers of ocular inflammatory pathology
- Classification and Clinical outcomes of patients with inflammatory and autoimmune arthritis



RESEARCH ACTIVITY

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Publications

- Altabás-González I, Rua-Figueroa I, Roberts K, Mamani IL, Mouriño C, Martínez-Barrio J, Izquierdo MG, Calvo-Alén J, Erasquin C, Serrano-Benavente B, Uriarte E, Tomero E, Freire-González M, Blanco R, Salgado E, Gomez-Sabater S, Fernández-Nebro A, Sangüesa C, Narváez J, Vázquez NM, Menor-Almagro R, de Salazar JCRG, Aurrecoechea E, Ibarguengoitia-Barrena O, Montilla C, Bonilla G, Segarra VT, Juan-Mas A, García-Villanueva MJ, Morales CM, Horcada L, Lozano-Rivas N, Iñiguez C, Arevalo M, Paredes B, Exposito L, Toyos EJ, Flores-Fernández E, Medina JN, Gil JJF, Bohorquez C, Pego-Reigosa JM. Validation of proposals for definitions of moderate and severe disease activity in SLE: impact on flares, quality of life, damage accrual, hospitalisations and mortality. *Lupus Sci Med*. 2025; 12(2): e001766. Article. IF: 4.2; Q1
- Atienza-Mateo B, Serrano-Combarro A, Martos JL, Vegas-Revenga N, López MM, Castañeda S, Melero-González RB, Vázquez NM, Carrasco-Cubero C, Morondo CD, Corredor DC, Rodríguez TRV, Valle AG, Bonilla G, López MR, Abascal IB, Herrera SMR, Sarmiento-Monroy JC, Brazal PA, Ferrer D, Ferraz-Amaro I, Blanco R. Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients. *Semin Arthritis Rheu*. 2025; 72: 152710. Article. IF: 3.8; Q2
- Balsa A, Andreu JL, Hermosa-Hernán JC, Pico JN, León-Navarro J, Venegas JJP, Romero-Yuste S, Sanmarti R, Gómez-Portillo AIT, Valenzuela-Gámez JC, Cohen J. Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project. *Reumatol Clin*. 2025; 21(1): 101800. Article. IF: 1.5; Q3
- Balsa A, Seoane-Mato D, Domínguez-Alvaro M, Alperi M, Ruiz-Esqueda V, Bachiller-Corral J, Díaz-González F. Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance

for rheumatoid arthritis. *AIMS and methodology. Reumatol Clin*. 2025; 21(5): 501895. Article. IF: 1.5; Q3

- Bauer CJ, Chrysidis S, Dejado C, Koster MJ, Kohler MJ, Monti S, Schmidt WA, Mukhtyar CB, Karakostas P, Milchert M, Ponte C, Duftner C, de Miguel E, Hocevar A, Iagnocco A, Terslev L, Dohn UM, Nielsen BD, Juche A, Seitz L, Keller KK, Karalilova R, Daikeler T, Mackie SL, Torralba K, van der Geest KSM, Boumans D, Bosch P, Tomelleri A, Aschwanden M, Kermani TA, Diamantopoulos A, Fredberg U, Inanc N, Petzinna SM, Albarqouni S, Behning C, Scha VS. Exploring the limit of image resolution for human expert classification of vascular ultrasound images in giant cell arteritis and healthy subjects: the GCA-USAI project. *Ann Rheum Dis*. 2025; 84(9): 1528-37. Article. IF: 24.0; D1
- Belletti M, Izquierdo-Escámez R, Tornero C, Olivas-Vergara O, Peiteado D, Carreño E. Safe use of corticosteroids in non-infectious uveitis. *J Inflamm Res*. 2025; 18: 14441-55. Review. IF: 4.6; Q2
- Benavent D, Iniasta-Chamorro J, Novella-Navarro M, Pérez-Martínez M, Martínez-Sánchez N, Kaffati M, Juárez-García M, Molinari-Pérez M, González-Torbay A, Gutiérrez M, López-Juanes N, Navarro-Compán V, Monjo-Henry I, Rodríguez-Rosales G, Bachiller J, Calvo-Aranda E, Michelena X, Berbel-Arcobé L, Balsa A, Gómez EJ, Plasencia-Rodríguez C. Digital health intervention for patient monitoring in immune-mediated inflammatory diseases: cocreation and feasibility study of the IMIDoc platform. *Jmir Hum Factors*. 2025; 12: e58095. Article. IF: 3.9; Q1
- Benavent D, Navarro-Compán V, Capelusnik D, Ramiro S. Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials. *Rheumatology*. 2025; 64(11): 5872-82. Article. IF: 4.7; Q1
- Benavent D, Tapia M, Bernabeu D, Muley J, Juárez M, Balsa A, Plasencia CH, Navarro-Compán. Can we identify axial spondyloarthritis among young adults referred to non-rheumatology

specialists? Results from the SHERPAS study. *Semin Arthritis Rheu*. 2025; 74: 152780. Article. IF: 3.8; Q2

- Blanco R, Aldasoro V, Maiz O, Melero R, Romero-Yuste S, de Miguel E, Ferraz-Amaro I, Lopez-Gutierrez F, Castaneda S, Loricera J, Tocilizumab in giant cell arteritis spanish collaborative group. tocilizumab in cranial and extracranial giant cell arteritis: a national multicentre study of 471 cases. *Rheumatology*. 2025; 64(5): 2928-36. Article. IF: 4.7; Q1
- Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, Keen HI, Ishii T, Khalidi N, Dejaco C, Cid MC, Hellmich B, Liu M, Zhao WH, Lagunes I, Romero AB, Wung PK, Merkel PA, (Blasa Criado A). A phase 3 trial of upadacitinib for giant-cell arteritis. *New Engl J Med*. 2025; 392(20): 2013-24. Article. IF: 84.5; D1
- Cobo-Ibáñez T, Castellví I, Pros A, Domínguez-Alvaro M, Nuño-Nuño L, Martínez-Barrio J, Jovaní V, Romero-Bueno F, Ruiz-Lucea E, Tomero E, Trallero-Araguás E, Narváez J, Camins-Fábregas J, Ruiz-Román A, Loarce-Martos J, Holgado-Pérez S, Flores-Rodríguez VM, Sivera F, Merino-Argumanez C, Juan-Mas A, Altabás-González I, Martín-López M, Belzunegui-Otano JM, Carrasco-Cubero C, Freire-González M, Rua-Figueroa I, Lozano-Rivas N, Suarez-Cuba JD, Martínez O, Ortega-Castro R, Alcocer P, Gómez-Gómez A, Sánchez-Pernaute O, Tandaipan JL, Carrión-Barberà I, Plasencia-Rodríguez C, Ibarguengoitia-Barrena O, Vidal-Montal P, Ortiz-Santamaría V, Garrido-Puñal N, Riveros A, Delgado-Frías E, López-Gómez JM, Barbadillo C, Pego-Reigosa JM, Joven-Ibáñez BE, Valero-Jaimes JA, Naveda E, Turrión-Nieves AI, Seoane-Mato D, Prado-Galbarro EJ, Puche-Larrubia MA. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisyntetase autoantibodies: data from the Myo-Spain registry. *Arthritis Res Ther*. 2025; 27(1): 5. Article. IF: 5.4; Q1
- Deodhar A, Navarro-Compán V, Poddubnyy D, Gensler LS, Ramiro S, Tomita T, Marzo-Ortega H,

Fleurinck C, Vaux T, Massow U, de Peyrecave N, van der Heijde D, Baraliakos X. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. *RMD Open*. 2025; 11(1): e005081. Article. IF: 5.3; Q1

- Edwards CJ, Kroenke G, Avouac J, Li ZG, Conti F, Balsa A, Mo DJ, Haladyj E, Fischer P, Tanaka M, Takita Y, Hagimori K, Takeuchi T. Baricitinib dose reduction in patients with rheumatoid arthritis achieving sustained disease control: final results from the RA-BEYOND study. *J Rheumatol*. 2025; 52(4): 316-22. Article. IF: 3.7; Q2
- Fernández-Fernández E, Brugarolas E, Monjo-Henry I, Novella-Navarro M, Balsa A, De Miguel E. The influence of the cardiac cycle on the halo sign and its impact on the ultrasound diagnosis of giant cell arteritis. *Rheumatology*. 2025; 64(3): 1459-63. Article. IF: 4.7; Q1
- García-Escudero P, López-Gómez M, López BM, Dorta AG, Frade-Sosa B, Lizarzaburu MS, Rúa-Figueroa I, Fiallo DV, de Miera EITS, Melero-González RB, Santos DD, Miranda JA, Belando CG, Boselli G, Boteanu AL, Villalobos L, Selaya CC, Santos CS, Álvarez ED, Font J, Alonso ER, Araguás ET, Merayo EE, Rodríguez-Laguna M, Monjo I, Gómez IV, Vela-Casasempere P, Merino C, Martínez MI, Beriain JAH, Ruiz-Román A, Calvo-Alén J. VEXAS syndrome through a rheumatologist's lens: insights from a Spanish national cohort. *Rheumatology*. 2025; 64(6): 3747-55. Article. IF: 4.7; Q1
- García-Salinas R, Mejia-Maggi N, Almada F, Magri S, Navarro-Compán V. Prevalence and clinical features of early axial spondyloarthritis according to ASAS definition: a cross-sectional analysis from the reuma-check cohort. *Rheumatol Int*. 2025; 45(5): 122. Article. IF: 3.5; Q2
- Garrido-Cumbrera M, Marzo-Ortega H, Correa-Fernández J, Christen L, Navarro-Compán V. Impact of working from home on the psychological well-being of 365 european patients with rheumatic diseases during COVID-19 pandemic. Results of the REUMAVID



3.3. Infectious Diseases and Immunity Area

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Study. *Musculoskeletal Care*. 2025; 23(2): e70094. Article. IF: 1.5; Q3

- **Gómez CMB, Plasencia-Rodríguez C, Novella-Navarro M, Martínez-Feito A, Balsa A, Calvo-Aranda E, Hernández-Breijo B.** Exosomal protein biomarkers in arthritis: deciphering the inflammatory profiles of RA and OA. *Biomedicines*. 2025; 13(6): 1283. Article. IF: 4.5; Q2
- **González-Gay MA, Ferraz-Amaro I, Castañeda S, Tasende JAP, Uriarte-Ecenarro M, Plaza Z, Sánchez-Alonso F, Gómez CG, González-Juanatey C, Llorca J, CARMA Project Collaborative Grp.** The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: results from the 10-year prospective CARMA cohort. *Rmd Open*. 2025; 11(1): e005352. Article. IF: 5.3; Q1
- **Ibarguengoitia-Barrena O, Riancho-Zarrabeitia L, Plaza Z, Rúa-Figueroa I, Roberts K, Martínez-Taboada V, Menor-Almagro R, Serrano-Benavente B, Rubio-Munoz P, Galindo-Izquierdo M, Fernández-Nebro A, Ruiz-Lucea ME, Calvo-Alen J, Tomero-Muriel EG, Uriarte-Isacelaya E, Pecondon-Espano A, Freire M, Garcia-Fernández J, Exposito L, Ibáñez-Barcelo M, Aurrecochea E, Montilla C, Salazar JRGD, García-Villanueva MJ, Cano-Alameda R, de Miera FJTS, Novoa-Medina FJ, Moriano-Morales C, Bonilla G, Narváez FJ, Andréu JL, Arévalo-Salaet M, Horcada L, Cobo T, Lozano-Rivas N, Bohórquez C, Iñiguez-Ubiaga CL, Salgado-Pérez E, Torrente-Segarra V, Monte TCS, Oller JE, Pego-Reigosa JM.** Serological clusters in systemic lupus erythematosus and its clinical and prognostic implications: A longitudinal cohort study. *Semin Arthritis Rheu*. 2025; 74: 152819. Article. IF: 3.8; Q2
- **Kaczmarczyk B, de la Calle-Fabregat C, Conde A, Duarte AC, Mena-Vazquez N, Fernández-Nebro A, Triguero-Martínez A, Castañeda S, Sobrin RDS, Mera-Varela A, Lopez-Pedreira C, Escudero-Contreras A, Vela-Casasempere P, Molina M, Narváez J, Retuerto-Guerrero M, Pablos JL, Sarmiento-Monroy JC, Sanmartí R, Gomez-Carrera L, Bonilla G, Remuzgo-**

- Martínez S, González-Gay MA, Leiro-Fernández V, Pérez-Gómez N, Vadillo-Font C, Abasolo L, Casafont-Sole I, Mateo-Soria L, Castillo-González AC, Marras C, Perez-Pampin E, Ballestar E, González A.** DNA methylome biomarkers of rheumatoid arthritis-associated interstitial lung disease reflecting lung fibrosis pathways, an exploratory case-control study. *Sci Rep-Uk*. 2025; 15(1): 15123. Article. IF: 4.9; Q1
- **Llorca J, Castaneda S, Ferraz-Amaro I, Plaza Z, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, González-Gay MA, (Bonilla G).** Performance of four cardiovascular risk scales in chronic inflammatory rheumatic disease patients: 10-year follow-up data. *Rheumatology*. 2025; 64(7): 4227-35. Article. IF: 4.7; Q1
- **Llorca J, Ferraz-Amaro I, Castañeda S, Raya E, Rodríguez-Rodríguez L, Rodríguez-Montero S, Sánchez-Nieves G, López-Meseguer A, Plaza Z, Sánchez-Alonso F, García-Gómez C, González-Juanatey C, González-Gay MA, (Bonilla G).** Evaluating the reliability of cardiovascular risk scales in patients with chronic inflammatory rheumatic diseases. *Semin Arthritis Rheu*. 2025; 72: 152694. Article. IF: 3.8; Q2
- **Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A, Plasencia-Rodríguez C.** Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. *Rheumatology*. 2025; 64(1): 344-51. Article. IF: 4.7; Q1
- **Martín-Gutiérrez A, Loricera J, Aldasoro V, Maiz O, de Miguel E, Galíndez-Agirregoikoa E, Ferraz-Amaro I, Castañeda S, Blanco R.** Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice. *Semin Arthritis Rheu*. 2025; 71: 152640. Article. IF: 3.8; Q2
- **Martín-Gutiérrez A, Loricera J, Prieto-Peña D, Aldasoro V, Maiz O, de Miguel E, Galíndez-Agirregoikoa E, Ferraz-Amaro I, Castaneda S, Blanco R.** Tocilizumab monotherapy versus combined in aortitis associated with giant cell arteritis: Factors associated with imaging remission in a multicenter open-label study of

196 patients. *Semin Arthritis Rheu*. 2025; 75: 152869. Article. IF: 3.8; Q2

- **Marzo-Ortega H, Navarro-Compán V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A.** Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies. *RMD Open*. 2025; 11(4): e006013. Article. IF: 5.3; Q1
- **Molina-Collada J, Domínguez-Álvaro M, Melero-González RB, de Miguel E, Silva-Díaz M, Jaimes JAV, González I, Martín JS, Narváez J, Calvet J, Casafont-Solé I, Ivorra JAR, Arrabal SL, Rocha MV, Iñiguez CL, Reyes MSB, Fernández CC, Villar MA, Mas AJ, Blanco R, ARTESER Project Collaborative Grp.** Mortality in patients with giant cell arteritis in Spain: results from the ARTESER registry. *Arthritis Res Ther*. 2025; 27(1): 4. Article. IF: 5.4; Q1
- **Molina-Collada J, Monjo-Henry I, Fernández-Fernández E, Alvaro-Gracia JM, de Miguel E.** The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up. *Rheumatology*. 2025; 64(3): 1448-52. Article. IF: 4.7; Q1
- **Monjo-Henry I, Nieto-Carvalho B, Uyaguari M, García-Carazo S, Balsa A, de Miguel E, Miranda-Carús ME.** Circulating PD-1hi CXCR5- and CXCR5+CD4 T cells are elevated in patients with newly diagnosed giant cell arteritis, and predict relapse. *Rheumatology*. 2025; 64(6): 3996-4004. Article. IF: 4.7; Q1
- **Monjo-Henry I, Uyaguari M, Nuño L, Nieto-Carvalho B, Fernández-Fernández E, Peiteado D, Villalba A, García-Carazo S, Balsa A, Miranda-Carús ME.** Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. *Rheumatology*. 2025; 64(2): 517-25. Article. IF: 4.7; Q1
- **Muñoz HMA, Molina-Collada J, Castrejón I, Monjo-Henry I, Fernández-Fernández E,**

Álvaro-Gracia JM, de Miguel E. Different giant cell arteritis phenotypes may present distinct types of ischaemic complications. *Clin Exp Rheumatol*. 2025; 43(4): 668-73. Article. IF: 3.2; Q2

- **Narváez J, Domínguez-Álvaro M, Hernández-Rodríguez I, de Miguel E, Silva-Díaz M, Belzunegui JM, Moriano C, Sánchez-Martín J, Lluch J, Calvo I, Aldasoro V, Abasolo L, Loricera J, Garrido N, Castañeda S, Vasques-Rocha M, Iñiguez CL, Hernández-Hernández V, Campos-Fernández C, Alcalde-Villar M, Juan-Mas A, Blanco R.** Epidemiology of major and minor relapses in giant cell arteritis according to EULAR definitions: insights from the ARTESER registry. *Rheumatology*. 2025; 64(9): 4985-94. Article. IF: 4.7; Q1
- **Navarro-Compán V, Reveille JD, Rahman P, Maldonado-Cocco JA, Magrey M, Bolce R, Panni T, Kronbergs A, Rudwaleit M.** Ixekizumab improves signs, symptoms, and quality of life in patients with axial spondyloarthritis irrespective of symptom duration. *Adv Ther*. 2025; 42(9): 4706-16. Article. IF: 4.7; Q1
- **Navarro-Compán V, Rudwaleit M, Dubreuil M, Magrey M, Marzo-Ortega H, Mease PJ, Walsh JA, Dougados M, de la Loge C, Fleurinck C, Massow U, Vaux T, Taieb V, Deodhar A.** Improved pain, morning stiffness, and fatigue with bimekizumab in axial spondyloarthritis: results from the phase III BE MOBILE Studies. *J Rheumatol*. 2025; 52(1): 23-32. Article. IF: 3.7; Q2
- **Navarro-Compán V, Sepriano A, Capelusnik D, Baraliakos X.** Axial spondyloarthritis. *Lancet*. 2025; 405(10473): 159-72. Article. IF: 109.0; D1
- **Navarro-Compán V, van den Bosch F, Sampaio-Barros PD, Östör AJK, Parikh B, Kato K, Gao TM, Stigler J, Ramiro S.** Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. *RMD Open*. 2025; 11(1): e005110. Article. IF: 5.3; Q1
- **Novella-Navarro M, González-Sánchez L, Hernández-Breijo B, de Diego RP, Sánchez-Corral P, López-Trascasa M, Miranda-Carús ME, Villalba A, Balsa A, De Miguel E, Plasencia-Rodríguez C, Corvillo F.** Serum adipon levels in rheumatic diseases: defining its role in disease



3.3. Infectious Diseases and Immunity Area

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

activity and progression in rheumatoid arthritis and axial spondyloarthritis. *Front Immunol.* 2025; 16: 1636158. Article. IF: 7.0; Q1

- Novella-Navarro M, van den Rym A, López-Pedrerá C, Martínez-Feito A, Nieto-Carvalho B, Reche K, López-Medina C, Escudero-Contreras A, Nozal P, Miranda-Carús ME, Monjo I, De Miguel E, Balsa A, Pérez-de Diego RPD, Plasencia-Rodríguez C. Do obesity and adipose tissue cytokines influence the response to janus kinase inhibitors in rheumatoid arthritis? *Nutrients.* 2025; 17(5): 820. Article. IF: 5.8; Q1
- Poddubnyy D, Baraliakos X, Navarro-Compán V, van der Heijde D. Response to the correspondence by Wendling et al on 'ASAS consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis'. *Ann Rheum Dis.* 2025; 84(6): e25-7. Letter. IF: 24.0; D1
- Poddubnyy D, Garrido-Cumbrera M, Sommerfleck F, Navarro-Compán V, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Davies J, Karam E. Diagnostic delay in patients from the international map of axial spondyloarthritis: geographic, sociodemographic and disease-related factors. *Rheumatology.* 2025; 64(4): 1873-9. Article. IF: 4.7; Q1
- Poddubnyy D, Navarro-Compán V, Torgutalp M, Arends S, Aydin SZ, Battista S, van den Bosch F, Bundy C, Cauli A, Davies J, Dougados M, Duruöz T, El-Zorkany B, Fong W, van Gaalen F, García-Salinas R, Cumbrera MG, Géher P, Gensler L, Grazio S, Huang F, Kishimoto M, Landewé R, Leung YY, Machado P, Marzo-Ortega H, Meghnathi B, Molto A, Nikiphorou E, Ramiro S, Rudwaleit M, Saad C, Sepriano A, Wei J, Baraliakos X, van der Heijde D. The assessment of spondyloarthritis international society (asas) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis. *Ann Rheum Dis.* 2025; 84(4): 538-46. Article. IF: 24.0; D1
- Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, Coombs D, Lagunes I, Biljan A, Nakasato P, Wung P, Lubrano E. Development of extramusculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis or axial spondyloarthritis.

Arthritis Rheumatol. 2025; 77(5): 536-46. Article. IF: 9.9; D1

- Rodríguez-Merlos P, Cabrera-Alarcón JL, Ruiz-Esquivé V, Chacur CA, Sanmartí R, de Miguel-Mendieta E, Álvaro-Gracia JM, Balsa A, Plasencia-Rodríguez C, Novella-Navarro M. Early-onset difficult-to-treat rheumatoid arthritis: proposal of data-driven predictors and temporal threshold. *Arthritis Res Ther.* 2025; 27(1): 153. Article. IF: 5.4; Q1
- Rua-Figueroa I, Pérez-Veiga N, Rodríguez-Almaraz E, Galindo-Izquierdo M, Erasquin C, Fernández-Nebró A, Itzazelaia EU, Serrano-Benavente B, Alén JC, Manrique-Ariza S, Senabre JM, Bernal JA, Naváez J, Tomero E, Aurrecoechea E, Ibáñez-Barceló M, Segarra VT, Sangüesa C, Freire-González M, García-Villanueva MJ, Taboada VM, Arevalo M, Morales CM, Iñiguez C, Perez A, Salgado E, Carrión-Barberá I, Andreu JL, Cobo T, Horcada L, Bonilla G, Lozano-Rivas N, Exposito L, Montilla C, Toyos EJ, Ibarguengoitia-Barrena O, Pascual EV, Medina JN, Menor-Almagro R, Ivorra JAR, Jiménez AM, Nolla JM, Pego-Reigosa JM. Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort. *Lupus Sci Med.* 2025; 12(2): e001633. Article. IF: 4.2; Q1
- Rudwaleit M, Navarro-Compán V, Russ H, Panni T, Filippi E, Nassab MH, Liu-Leage S, Goëb V, Ciccía F, Dudler J. BASDAI and ASDAS disease states in relationship to ASAS40 response: post hoc analysis of ixekizumab in radiographic axial spondyloarthritis. *Rheumatol Adv Pract.* 2025; 9(2): rka012. Article. IF: 2.8; Q2
- Salmoral A, Peris P, Medina CL, Flórez H, Barceló M, Pastor MP, Ros I, Grados D, Aguado P, García S, López L, Gifre L, Cerdá D, Aguilar EJ, Panero B, Costa E, Casado E, Hernández B, Ferrer AM, Graña J, Gómez I, Guañabens N, Spanish Soc Rheumatology. Bisphosphonate drug holidays in osteoporosis according to fracture risk profile. *Osteoporosis Int.* 2025; 36(2): 245-54. Article. IF: 5.4; Q1
- Sawada H, Kishimoto M, Tada K, Deshpande GA, Kobayashi D, Okada M, Benavent D, Plasencia-Rodríguez C, Navarro-Compán V,

López-Medina C, Molto A, Dougados M, Tamura N. Disease phenotype and management of axial psoriatic arthritis in Japan compared with other regions, particularly other Asian countries: results of the ASAS-PerSpA study. *Bmc Rheumatol.* 2025; 9(1): 130. Article. IF: 3.1; Q2

- Schremmer T, Dejaco C, Recker F, Aschwanden M, Boumans D, Bruyn GA, Chrysosidis S, Daikeler T, Nielsen B, de Miguel E, Diamantopoulos AP, Dohn UM, Duftner C, Germano G, Haagsma C, Hartung W, Hocevar A, Iagnocco A, Juche A, Karakostas P, Karalilova R, Keller KK, Sarker B, Smith K, Tischler V, Macchioni P, Milchert M, Monti S, Mukhtyar C, Naredo E, Schmidt WA, Seitz L, Terslev L, Wakefield RJ, Schäfer VS. OMERACT GCA phantom project: validation of a 3D-printed ultrasound training phantom for diagnosis of giant cell arteritis. *Rmd Open.* 2025; 11(1): e005316. Article. IF: 5.3; Q1
- Serrano-Combarro A, Atienza-Mateo B, Martín-Gutiérrez A, Loarce-Martos J, Dubuc CAE, Mena MP, Melero-González RB, Lopez MM, Vazquez NM, Carrasco-Cubero C, García CP, Valle AG, Bonilla G, Madrigal JMB, Astigarraga-Urquia U, Revenga NV, Albadaledo LP, Castro RO, Palma-Sánchez D, Ortiz AMF, Viejo PL, Lasanta ML, Bufort MG, Sole IC, Lamua-Riazuelo JR, Abascal IB, Ruiz-Esquivé V, Perez ECC, Robles BJF, Martinez-Vidal MP, Morales JM, Urruticoechea-Arana A, Rosas J, Fernández-Lozano D, Corredor DC, Ferraz-Amaro I, Castaneda S, Blanco R. Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients. *Rheumatology.* 2025; 64(10): 5471-80. Article. IF: 4.7; Q1
- Tornero C, Martos-Moreno GA, Guañabens N, Flórez H, Ribera A, Aguado P. Clinical characterization and impact of hypophosphatasia in Spain: An observational analysis of the Spanish cohort included in the Global HPP Registry. *Med Clin-Barcelona.* 2025; 165(5): 107120. Article. IF: 2.8; Q1
- van der Heijde D, Navarro-Compán V, Landewé R, Sieper J, van Gaalen F, Gensler LS, Machado PM, Marzo-Ortega H, Poddubnyy D, Protopopov M, Ramiro S, Sepriano A, Baraliakos X. 1995-2025: thirty years of ASAS and its contribution to the

understanding of spondyloarthritis. *Ann Rheum Dis.* 2025; 84(3): 382-7. Article. IF: 24.0; D1

- Van Gaalen FA, Navarro-Compán V, Baraliakos X, van den Bosch F, Gensler LS, Hmamouchi I, Landewé R, Machado PM, Marzo-Ortega H, Rodríguez VR, Poddubnyy D, Ramiro S, van der Heijde D. ASAS recommendations on reporting axial spondyloarthritis clinical trials. *Ann Rheum Dis.* 2025; 84(11): 1770-8. Article. IF: 24.0; D1
- Villalba A, Nuno L, Benito-Miguel M, Nieto-Carvalho B, Monjo I, Novella-Navarro M, Peiteado D, García-Carazo S, Balsa A, Miranda-Carús ME. Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis. *Rheumatology.* 2025; 64(4): 2282-9. Article. IF: 4.7; Q1

Research projects

- Aguado Acín P. Caracterización e historia natural de la hipofosfatasa en pacientes adultos con confirmación genética frente a pacientes con fosfatasa alcalina baja y test genético negativo. Hipofosfatasa del adulto. Alexion Pharmaceutical Inc. 2017-Ongoing. **Management centre:** FIBHULP
- de Miguel Mendieta E. Análisis de imágenes ecográficas para el diagnóstico de arteritis de células gigantes mediante técnicas de deep learning. Roche Farma S.A. 2021-Ongoing. **Management centre:** FIBHULP
- Miranda Carús ME. Células t helper foliculares t foliculares reguladoras y t helper periféricas en artritis reumatoide preclínica, temprana y establecida: herramientas para la medicina personalizada (PI20/00141). ISCIII. 2021-2025. **Management centre:** FIBHULP
- Miranda Carús ME. Efecto del metotrexato en la frecuencia y función de las células T helper foliculares; implicaciones patogénicas y pronósticas. Laboratorios Gebro Pharma S. A. 2020-Ongoing. **Management centre:** FIBHULP
- Miranda Carús ME. Frecuencia y función de las células T helper foliculares circulantes y plasmablastos en pacientes con artritis reumatoide, y su relación con los niveles de autoanticuerpos: modificaciones asociadas con el bloqueo de la coestimulación por Abatacept. Bristol

3.3. Infectious Diseases and Immunity Area

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Myers Squibb S. A. U. 2016-Ongoing. **Managment centre:** FIBHULP

- **Miranda Carús ME.** Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints (SPIDeRR_EUGENIA MIRANDA). UE. 2023-2028. **Managment centre:** FIBHULP
- **Navarro Compán MV.** Resonancia magnética de sacroilíacas y desarrollo de un cuestionario para identificar espondiloartritis axial precoz en pacientes con dolor lumbar crónico remitidos a otros especialistas distintos al reumatólogo. Novartis Farmaceutica S.A. 2021-Ongoing. **Managment centre:** FIBHULP
- **Peiteado Lopez MD.** ERfficacy, safety and costeffectiveness of methotrexate, adalimumab, or their combination in non infectious non anterior uveitis: a multicenter, randomized, parallel 3 arm, active-controlled, phase 3 open label with blinded outcome assessment study (5681 CO-THEIA). Fundacion para la Investigacion Biomedica del Hospital Clinico San Carlos. 2021-2025. **Managment centre:** FIBHULP
- **Plasencia Rodríguez, C.** Hacia la telemonitorización en enf. Inflammatorias inmunomediadas: implementación de un modelo asistencial mixto en una unidad de terapias complejas (PI22/00777). ISCIII. 2023-2027. **Managment centre:** FIBHULP

Clinical trials

- **Aguado Acín P.** A multicenter, open-label, phase 1/2, dose-escalation and subsequent safety extension study of subcutaneous kk8123 in adult patients with x-linked hypophosphatemia. **Type/Phase:** II **Sponsored by:** Kyowa Kirin Farmaceutica SL. **Signature date:** 11/12/2025
- **Aguado Acín P.** A multicenter, open-label, phase 1/2, dose-escalation and subsequent safety extension study of subcutaneous kk8123 in adult patients with x-linked hypophosphatemia. **Type/Phase:** II **Sponsored by:** Kyowa Kirin Farmaceutica SL. **Signature date:** 14/03/2025
- **Bohorquez Heras C.** Systemic lupus erythematosus longitudinal cohort generation and multi-omics characterization" (smiles project) generación de una

cohorte longitudinal y caracterización multiómica del lupus eritematoso sistémico (proyecto smiles).

- Type/Phase:** OTROS **Sponsored by:** Fundacio Hospital Vall D'Hebron. **Signature date:** 05/03/2025
- **Bonilla Hernán MG.** Anexo 1 6503 a phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in participants with sjögren's syndrome with moderate-to-severe systemic disease activity. **Type/Phase:** III **Sponsored by:** Horizon Therapeutics Ireland Dac. **Signature date:** 21/01/2025
- **Bonilla Hernán MG.** Eficacia y seguridad de sar441344 para el tratamiento del lupus eritematoso sistémico: estudio aleatorizado, doble ciego, controlado con placebo, fase 2, prueba de concepto. **Type/Phase:** II **Sponsored by:** Sanofi Aventis S.A. **Signature date:** 28/01/2025
- **Bonilla Hernán MG.** Observational retrospective study to describe characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating saphnelo (anifrolumab) in a real-world setting. Estudio azahar. **Type/Phase:** EOm no prospectivo **Sponsored by:** Astrazeneca Farmaceutica Spain S.A. **Signature date:** 04/02/2025
- **De Miguel Mendieta E.** A phase 3, parallel-group, randomized, double-blind, 4-arm, placebo-controlled, multicenter study with risankizumab as active reference arm to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis and previous inadequate response or intolerance to tumor necrosis factor- α inhibitors. **Type/Phase:** III **Sponsored by:** Moonlake Immunotherapeutics Ag. **Signature date:** 20/02/2025
- **De Miguel Mendieta E.** Estudio de fase 3 para evaluar la eficacia y la seguridad del zasocitinib (tak-279) en sujetos con artritis psoriásica activa estratificados por uso previo de biofármacos. **Type/Phase:** III **Sponsored by:** Takeda Development Center Americas. **Signature date:** 18/11/2025

- **De Miguel Mendieta E.** Estudio de fase 3 para evaluar la eficacia y la seguridad del zasocitinib (tak-279) en sujetos con artritis psoriásica activa estratificados por uso previo de biofármacos. **Type/Phase:** III **Sponsored by:** Takeda Development Center Americas. **Signature date:** 29/01/2025
- **De Miguel Mendieta E.** Estudio de fase 3b/4, aleatorizado, comparativo con un tratamiento activo, con grupos paralelos, en el que se evalúa baricitinib en pacientes con artritis reumatoide. **Type/Phase:** III **Sponsored by:** Lilly, S.A. **Signature date:** 24/01/2025
- **De Miguel Mendieta E.** Estudio en fase III, aleatorizado, con doble enmascaramiento, de tres grupos paralelos, comparativo con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes de ambos sexos de 18 años en adelante con artritis psoriásica activa que no han recibido antes tratamiento con farma biológicos. **Type/Phase:** III **Sponsored by:** Moonlake Immunotherapeutics Ag. **Signature date:** 13/03/2025
- **De Miguel Mendieta E.** Peris: prospective multi-country, real-world, multi-arm study of treatment persistence with risankizumab in psoriatic arthritis. Peris: estudio prospectivo en vida real sobre la persistencia del tratamiento con risankizumab para la artritis psoriásica en varios países. **Type/Phase:** EOm prospectivo **Sponsored by:** Abbvie Spain S. L. U. **Signature date:** 14/02/2025
- **De Miguel Mendieta E.** Programa en fase III aleatorizado, comparativo con placebo, doble ciego y con grupos paralelos para evaluar la eficacia y la seguridad de filgotinib en participantes adultos con espondiloartritis axial activa. **Type/Phase:** III **Sponsored by:** Alfasigma S.P.A Galapagos NV. **Signature date:** 06/10/2025
- **De Miguel Mendieta E.** Programa en fase III aleatorizado, comparativo con placebo, doble ciego y con grupos paralelos para evaluar la eficacia y la seguridad de filgotinib en participantes adultos con espondiloartritis axial activa.

- Type/Phase:** III **Sponsored by:** Alfasigma S.P.A Galapagos NV. **Signature date:** 09/12/2025
- **De Miguel Mendieta E.** Randomised, multicentre, double-blind clinical trial to evaluate the efficacy and safety of montelukast vs. placebo in patients with erosive/inflammatory osteoarthritis of the hands. mother study. **Type/Phase:** III **Sponsored by:** Farmlider Sa. **Signature date:** 14/11/2025
- **Navarro Compán MV.** Estudio axioma: axial spondyloarthritis international outcome assessment. **Type/Phase:** No EPA **Sponsored by:** Maatschap Reumatologie Heelen/ Sittard. **Signature date:** 03/11/2025

Patents and trademarks

- **Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee.** Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.
- **Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D'Hebron - Institut de Recerca (VHIR), assignees.** Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.
- **Plasencia C.** Trademark name: MAM Modelo Asistencial Mixto; CM 18637540; 2022 January 13.

